Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
Human melanoma cells (from biopsies and culture) express sialyl-Lewis(x) and sialyl Lewis(a), the ligands for ECAM. These ligands may facilitate tumor progression and metastasis in human cancers. To test whether the antibodies to these ligands inhibit tumor progression, IgG and IgM responses to sLe(x) and sLe(a) were induced in C57BL/6j mice (n = 76) by immunization with human melanoma cells, with or without adjuvants (BCG, MPL, KLH). Control mice were treated with saline or BCG. Tumor growth and antigen expression were monitored after challenge with B16 mouse melanoma cells expressing sLe(x), sLe(a) and the ganglioside GM3. Tumor growth was reduced in mice immunized with BCG alone or cells with BCG or MPL, while tumors in mice receiving cells without adjuvants grew larger than in the control. Augmentation of IgM titers to sLe(x) and GM3 after immunization with BCG, or with cells with BCG or MPL correlated with retarded tumor growth, while increased IgG titers to sLe(x) significantly correlated with aggressive tumor growth in mice immunized with cells without adjuvants. SLe(x), sLe(a) and GM3 were expressed in tumors from mice treated with saline or BCG. SLe(x) expression, in particular, was lost in tumors growing in mice immunized with cells with or without adjuvants. Anti-sLe(x) antibodies may promote or prevent tumor growth by antigenic modulation or by cytotoxic killing of tumor cells. Since early anti-sLe(x) IgM correlated with tumor regression, in contrast to anti-sLe(x) IgG, it may serve as a potential early endpoint for the effectiveness of melanoma vaccines expressing the antigens.
Ravindranath
M H
MH
Laboratory of Glycolipid Immunotherapy, John Wayne Cancer Institute, Santa Monica, CA, USA. ravi@jwci.org
Kelley
M C
MC
Jones
R C
RC
Amiri
A A
AA
Bauer
P M
PM
Morton
D L
DL
D000818:Animals; D000912:Antibodies, Neoplasm / Q000378:metabolism*; D001500:BCG Vaccine / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002455:Cell Division; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005679:G(M3) Ganglioside / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism*; D007075:Immunoglobulin M / Q000378:metabolism*; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D016256:Lewis X Antigen / Q000276:immunology*; D008297:Male; D008546:Melanoma, Experimental / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL
D000912:Antibodies, Neoplasm; D001500:BCG Vaccine; D019496:Cancer Vaccines; D005679:G(M3) Ganglioside; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007983:Lewis Blood Group Antigens; D016256:Lewis X Antigen